[1] |
XIE Mengqing, CHU Xiangling, ZHOU Juan, SU Chunxia.
The advances in immunotherapy biomarkers of small cell lung cancer
[J]. China Oncology, 2021, 31(7): 635-639.
|
[2] |
HU Guannan , CHEN Lei , ZHOU Liangping , ZHOU Zhengrong .
A case report of pulmonary malignant melanoma complicated with lung adenocarcinoma and literature review
[J]. China Oncology, 2021, 31(7): 647-650.
|
[3] |
YI Weili , ZHAO Wencheng , HUANG Dongning , QIN Li , WU Xintian , ZHOU Fei , WU Fengying .
Analysis of immune-related adverse events and its correlation with efficacy of anti-PD-1 monotherapy in advanced non-small cell lung cancer
[J]. China Oncology, 2021, 31(3): 203-211.
|
[4] |
LIANG Xiang , WU Yunteng .
Clinical characteristics and prognosis of long-term survivors of oral mucosal melanoma with recurrence and metastasis
[J]. China Oncology, 2020, 30(7): 531-537.
|
[5] |
ZHAO Haiyun, WU Xiaohua.
Research progress of immunotherapy in ovarian cancer
[J]. China Oncology, 2020, 30(7): 538-545.
|
[6] |
YANG Xiaoling, SI Lu, MAO Lili, WANG Xuan, CUI Chuanliang, CHI Zhihong, SHENG Xi’nan, GUO Jun.
Adverse events of pembrolizumab in patients with advanced melanoma and correlation analysis
[J]. China Oncology, 2020, 30(5): 362-368.
|
[7] |
WANG Ping, YANG Wenxiu, ZHOU Jie, FENG Jianglong, LIN Chaoqun.
The correlation of NF-κB/p65, PD-1 and PD-L1 expressions and their clinical significance in diffuse large B-cell lymphoma
[J]. China Oncology, 2020, 30(5): 375-382.
|
[8] |
XU Wencai, GUO Leiming, CUI Yingying, LIU Xiao, JIANG Yue, GE Hong.
The effect of lung stereotactic body radiotherapy on peripheral blood lymphocytes
[J]. China Oncology, 2020, 30(12): 1013-1016.
|
[9] |
LUO Qian , ZOU Liqun .
Research progress of PD-1/PD-L1 inhibitors in the treatment of peripheral T-cell lymphomas
[J]. China Oncology, 2020, 30(12): 1035-1040.
|
[10] |
LI Guoyu , HE Ming .
New progress in the research of immunotherapy for extensive-stage small cell lung cancer
[J]. China Oncology, 2020, 30(10): 826-833.
|
[11] |
ZHOU Hongyu, CHEN Lihua, LI Haoran, CHENG Xi.
The role of c-kit in the treatment and prognosis of primary female genital malignant melanoma: current status and prospects
[J]. China Oncology, 2020, 30(10): 834-840.
|
[12] |
PAN Zeyan, ZHAN Xianbao.
Current status and future strategies of chimeric antigen receptor T-cells in the treatment of pancreatic cancer
[J]. China Oncology, 2019, 29(7): 481-485.
|
[13] |
CHEN Liuhan, ZHANG Yangyang, LI Xian’an.
Analysis of clinical characteristics and prognostic factors of acral melanoma
[J]. China Oncology, 2019, 29(5): 362-371.
|
[14] |
PAN Yingying, ZHOU Fei, ZHOU Caicun.
The perspects and challenges of immunotherapy for lung cancer
[J]. China Oncology, 2019, 29(4): 241-249.
|
[15] |
CAO Xiaoshan, CONG Binbin.
The progress of treatment for triple-negative breast cancer in the era of precision medicine
[J]. China Oncology, 2019, 29(12): 971-976.
|